Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.75 GBX | 0.00% | +5.62% | +19.29% |
05/04 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
05/04 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Valuation
Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 8.812 | 10.13 | 31.39 | 10.87 | 11.43 | 7.292 | - | - |
Enterprise Value (EV) 1 | 8.812 | 8.158 | 25.34 | 8.213 | 9.941 | 3.633 | 4.346 | 4.092 |
P/E ratio | - | -12.4 x | -17.3 x | -5.26 x | -5.7 x | -2.71 x | -7.83 x | 16.8 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 19 x | 20.7 x | 20.5 x | 6.69 x | 5.24 x | 3.25 x | 2.22 x | 1.71 x |
EV / Revenue | 19 x | 16.7 x | 16.6 x | 5.05 x | 4.56 x | 1.62 x | 1.33 x | 0.96 x |
EV / EBITDA | -21.7 x | - | -22 x | -4.34 x | - | -2.05 x | -5.14 x | 6.02 x |
EV / FCF | - | - | - | - | - | -2.02 x | -5.43 x | 5.85 x |
FCF Yield | - | - | - | - | - | -49.6% | -18.4% | 17.1% |
Price to Book | - | - | - | - | - | 1.05 x | 1.21 x | 1.11 x |
Nbr of stocks (in thousands) | 14,687 | 14,687 | 22,185 | 22,185 | 22,185 | 62,060 | - | - |
Reference price 2 | 0.6000 | 0.6900 | 1.415 | 0.4900 | 0.5150 | 0.1175 | 0.1175 | 0.1175 |
Announcement Date | 17/07/19 | 13/07/20 | 12/07/21 | 11/07/22 | 26/07/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 0.463 | 0.489 | 1.528 | 1.625 | 2.179 | 2.244 | 3.28 | 4.274 |
EBITDA 1 | -0.407 | - | -1.151 | -1.894 | - | -1.77 | -0.845 | 0.68 |
EBIT 1 | - | -0.941 | -1.551 | -2.352 | -2.306 | -2.109 | -1.162 | 0.33 |
Operating Margin | - | -192.43% | -101.51% | -144.74% | -105.83% | -93.96% | -35.45% | 7.72% |
Earnings before Tax (EBT) 1 | - | -0.897 | -1.594 | -2.36 | -2.332 | -2.164 | -1.282 | 0.29 |
Net income 1 | - | -0.816 | -1.451 | -2.067 | - | -1.835 | -0.992 | 0.435 |
Net margin | - | -166.87% | -94.96% | -127.2% | - | -81.76% | -30.25% | 10.18% |
EPS 2 | - | -0.0555 | -0.0820 | -0.0932 | -0.0903 | -0.0434 | -0.0150 | 0.007000 |
Free Cash Flow 1 | - | - | - | - | - | -1.8 | -0.8 | 0.7 |
FCF margin | - | - | - | - | - | -80.2% | -24.39% | 16.38% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 102.94% |
FCF Conversion (Net income) | - | - | - | - | - | - | - | 160.92% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 17/07/19 | 13/07/20 | 12/07/21 | 11/07/22 | 26/07/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2024 S1 | 2024 S2 |
---|---|---|
Net sales | - | - |
EBITDA | - | - |
EBIT 1 | - | -0.81 |
Operating Margin | - | - |
Earnings before Tax (EBT) | - | - |
Net income 1 | -1.01 | -0.825 |
Net margin | - | - |
EPS 2 | -0.0455 | -0.0204 |
Dividend per Share | - | - |
Announcement Date | 18/12/23 | - |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | - | 1.98 | 6.05 | 2.66 | 1.48 | 3.66 | 2.95 | 3.2 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | - | - | -1.8 | -0.8 | 0.7 |
ROE (net income / shareholders' equity) | - | - | - | - | - | -28% | -17.5% | 7% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | - | 0.1100 | 0.1000 | 0.1100 |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | 0.62 | 0.9 | 0.45 | 0.25 | 0.07 | 0.1 |
Capex / Sales | - | - | 40.58% | 55.63% | 20.61% | 11.14% | 1.98% | 2.34% |
Announcement Date | 17/07/19 | 13/07/20 | 12/07/21 | 11/07/22 | 26/07/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.29% | 9.11M | |
+8.66% | 219B | |
+8.46% | 185B | |
+14.25% | 135B | |
+27.77% | 107B | |
+15.07% | 51.28B | |
+4.48% | 51.01B | |
+4.40% | 41.85B | |
+6.62% | 37.02B | |
+25.91% | 31.27B |
- Stock Market
- Equities
- AOR Stock
- Financials RUA Life Sciences plc